Exercises for Rehabilitation of COgnition and Lifestyle Enhancement in Patients With Mild Cognitive Impairment
NCT07517380, Not applicable, Recruiting, Casa di Cura IGEA
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Exercises for Rehabilitation of COgnition and Lifestyle Enhancement in Patients With Mild Cognitive Impairment | ClinicalTrials.gov |
| NCT number | NCT07517380 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Casa di Cura IGEA | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment (MCI) | ClinicalTrials.gov |
| Interventions | Multimodal Group Cognitive Rehabilitation Intervention, Active Control | ClinicalTrials.gov |
| First posted | 2026-04-08 | ClinicalTrials.gov |
| Last updated | 2026-04-08 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment (MoCA) score | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | The Montreal Cognitive Assessment (MoCA) is a cognitive test specifically developed for the detection of MCI and is recommended as the preferred tool for screening patients with suspected MCI. Scores range from 0 to 30, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Forward Digit span | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses verbal short-term memory. Scores range from 0 to 9, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Copy of the Modified Taylor Complex Figure | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | This test evaluates visual-constructional ability. Scores range from 0 to 36, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Rey Auditory Verbal Learning Test (RAVLT) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates the ability to encode, consolidate, store, recall, and recognize verbal information. | ClinicalTrials.gov |
| Primary | Boston Naming Test (BNT) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses the ability to retrieve the names of visually presented objects. | ClinicalTrials.gov |
| Primary | Multiple Features Target Cancellation (MFTC) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It requires detecting stimuli characterized by a conjunction of visual features, assessing selective attention and visuospatial exploration. | ClinicalTrials.gov |
| Primary | Raven's Colored Progressive Matrices (CPM) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates nonverbal abstract reasoning. | ClinicalTrials.gov |
| Primary | Semantic and phonemic fluency | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates generative language production under restricted search conditions, thus assessing both language ability and executive functions. | ClinicalTrials.gov |
| Primary | Trail Making Test (TMT) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assess psychomotor speed, visual attention, and visuomotor coordination in both part A and part B and set-shifting ability in part B. | ClinicalTrials.gov |
| Primary | Weigl sorting test (WST) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates non verbal executive functions (visual categorization and self monitoring). | ClinicalTrials.gov |
| Primary | Stroop color word test | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assess inhibition mechanisms. | ClinicalTrials.gov |
| Primary | Questionnaire on lifestyle | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It has been developed ad hoc to detect any changes in lifestyle occurring after the intervention. | ClinicalTrials.gov |
| Primary | Forward Corsi span. | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses visuo-spatial short-term memory. Scores range from 0 to 9, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Backward Digit span. | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses verbal working memory. Scores range from 0 to 8, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Backward Corsi span | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesse visuospatial working memory. Scores range from 0 to 8, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Free recall of the Modified Taylor Complex Figure | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses visuospatial long-term memory. Scores range from 0 to 36, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Primary | Recognition of the Modified Taylor Complex Figure | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses visuospatial long-term memory (recognition component). Scores range from 0 to 10, with higher scores indicating better cognitive function. | ClinicalTrials.gov |
| Secondary | Functional Activities Questionnaire (FAQ) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates functional autonomy in complex everyday activities. | ClinicalTrials.gov |
| Secondary | Neuropsychiatric Inventory Questionnaire (NPI-q) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It assesses a wide range of neuropsychiatric symptoms. | ClinicalTrials.gov |
| Secondary | Geriatric Depression Scale (GDS) | Data will be collected at T0 (baseline), T1 (upon completion of the 12-week treatment), and T2 (six months after baseline). | It evaluates depressive symptoms in geriatric population. Scores range from 0 to 30, with scores higher than 9 indicating depressive symptoms. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 10
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Primary outcome | ConductCognition |
| Corsi Block-Tapping Test | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Matrix Reasoning | Primary outcome | ConductCognition |
| Picture Naming Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)